BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024

June 3, 2024

https://www.globenewswire.com/news-release/2024/06/03/2892563/0/en/BridgeBio-to-Host-Call-on-Month-12-and-18-Phase-2-Cohort-5-Results-of-Oral-Infigratinib-in-Achondroplasia-on-June-4-2024.html

PALO ALTO, Calif., June 03, 2024 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq:BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that members of its management team, along with Ravi Savarirayan, M.D., Ph.D., of Murdoch Children’s Research Institute in Melbourne, Australia, and the global lead investigator for PROPEL 2, will host a call on June 4, 2024, at 8:00 am ET to share results from Month 12 and Month 18 from Cohort 5 of PROPEL 2, a Phase 2 trial of the investigational oral therapy infigratinib in children with achondroplasia.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.